SCHEDULE: Brio Capital Discloses 9.99% Stake in Sigyn Therapeutics
Beneficial Ownership Disclosure
Brio Capital Master Fund Ltd. and Brio Capital Management LLC have filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in SIGYN THERAPEUTICS, INC. as of December 31, 2025.
Summary
- Brio Capital Master Fund Ltd. and Brio Capital Management LLC (collectively, the "Reporting Persons") jointly filed an Amendment No. 8 to Schedule 13G.
- The filing reports beneficial ownership of 160,537 shares of common stock in SIGYN THERAPEUTICS, INC.
- This represents 9.99% of the issuer's common stock outstanding.
- The percentage calculation is based on 1,605,377 shares of common stock outstanding as of November 14, 2025, as reported in the Issuer's Form 10-Q.
- The beneficially owned amount includes 84,608 shares of common stock and additional shares issuable upon exercise of warrants, convertible notes, and convertible preferred shares.
- A blocker provision is in place, excluding shares from the calculation if their exercise would result in ownership exceeding 9.99% of the outstanding shares.
- Shaye Hirsch, as Managing Member of Brio Capital Management LLC, makes voting and investment decisions for Brio Capital Master Fund Ltd.
- The Reporting Persons certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the issuer's future operations or financial performance.
Management Comments
- Shaye Hirsch, in his capacity as Managing Member of Brio Capital Management LLC, makes voting and investment decisions on behalf of Brio Capital Management LLC in its capacity as the investment manager of Brio Capital Master Fund Ltd.
Industry Context
This filing is a standard disclosure of beneficial ownership by an investment fund, indicating a significant but non-controlling stake in SIGYN THERAPEUTICS, INC. It does not provide information on broader industry trends or competitive landscape.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | No management changes are reported in this filing. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | No changes in bylaws, committees, policies, or procedures are reported in this filing. | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company.
- Market: Confirms a substantial, but non-controlling, investment by Brio Capital in SIGYN THERAPEUTICS, INC.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2025-11-14 | Date as of which 1,605,377 shares of common stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-12-31 | Date of event which requires the filing of this statement. |
| 2026-01-13 | Signature date of the Schedule 13G filing by Brio Capital Master Fund Ltd. and Brio Capital Management LLC. |
Keywords
SIGYN THERAPEUTICS, Brio Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.